ArticleDiscover oncology2025
Integrated pan-cancer and melanoma-specific analysis of angiopoietin-2: prognostic value, immune microenvironment modulation, and ceRNA network regulation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A novel prognostic model based on MVIRGs identifies ANGPT2 as a key target driving the malignant progression of HCC.Biological procedures online · 2026Article
- Integrative In Silico and FFPE Tissue Analyses Elucidate Upregulated Genes in Colorectal Cancer Enriched for Tie2-Expressing Macrophages/Monocytes.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveThis research seeks to comprehensively explore the expression patterns of Angiopoietin-2 (ANGPT2) in pan-cancer and examine its relationship with clinical outcomes, tumor immune microenvironment dynamics, and biological functions, with particular emphasis on skin cutaneous melanoma (SKCM).
methodsData from six databases, including UCSC Xena, TCGA, GTEx, TIMER2.0, GEPIA, and cBioPortal, were analyzed to assess ANGPT2 expression in pan-cancer. Immunohistochemical images were sourced from the HPA database. We explored the correlation between ANGPT2 expression and prognosis, diagnostic value, genetic alterations, and immune cell infiltration in cancers. Functional enrichment and gene set enrichment analyses were performed to uncover the biological roles of ANGPT2. Additionally, miRWalk, miRDB, Starbase 2.0 ENCORI, and Cytoscape were utilized to identify and construct the lncRNA-miRNA-ANGPT2 ceRNA regulatory network in SKCM.
resultsOur comprehensive pan-cancer analysis revealed that ANGPT2 undergoes genetic alterations in several tumor types, including mutations, amplifications, and deep deletions. ANGPT2 expression varies across cancers, with high levels detected in 21 tumor types. ANGPT2 demonstrated significant diagnostic and prognostic value in various cancers. Genes related to ANGPT2 in cancers with high expression were found to be involved in critical pathways such as tumor angiogenesis, growth factor signaling, extracellular matrix (ECM) structure, and cell surface receptor activation. In addition, ANGPT2 was found to modulate the immune microenvironment in multiple tumors, promoting immune evasion and contributing to tumor progression, particularly in SKCM. A lncRNA-miRNA-ANGPT2 ceRNA regulatory network was identified, which may play a role in SKCM progression.
conclusionsANGPT2 demonstrates potential as a biomarker for cancer diagnosis and prognosis, with evidence suggesting its involvement in immune microenvironment regulation and associated gene networks. Therapeutic approaches targeting ANGPT2, either as a stand-alone treatment or in combination with immunotherapies, could offer new and effective strategies for future cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.